Alnylam Pharmaceuticals IncAlnylam expands use of Komodo's AI platform, enhancing data-driven decision-making across its enterprise.

Komodo Health announced an expanded strategic partnership with Alnylam Pharmaceuticals to scale its analytics AI platform, Marmot, across key enterprise functions at Alnylam. Alnylam, an early adopter of Marmot since August 2025, initially focused on building custom AI agents for its commercial business function. The expanded agreement will deploy Marmot across Alnylam's customer-facing organization and more broadly across the enterprise, creating a unified foundation for data-driven decision-making. Komodo also unveiled new Marmot capabilities designed to move organizations beyond AI experimentation and into enterprise-wide intelligence, including features that make healthcare data accessible to all users while ensuring reproducibility and scientific rigor.
Alnylam Pharmaceuticals IncAlnylam expands use of Komodo's AI platform, enhancing data-driven decision-making across its enterprise.
Komodo Health expands partnership with Alnylam, scaling its Marmot platform across the enterprise, indicating strong customer adoption.